Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F19%3A00012699" target="_blank" >RIV/75010330:_____/19:00012699 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0163445319303329?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0163445319303329?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jinf.2019.10.018" target="_blank" >10.1016/j.jinf.2019.10.018</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Popis výsledku v původním jazyce

The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) world-wide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,00 0 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended. Crown Copyright (C) 2019 Published by Elsevier Ltd on behalf of The British Infection Association.

Název v anglickém jazyce

Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Popis výsledku anglicky

The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) world-wide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,00 0 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended. Crown Copyright (C) 2019 Published by Elsevier Ltd on behalf of The British Infection Association.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Infection

ISSN

0163-4453

e-ISSN

1532-2742

Svazek periodika

79

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

528-541

Kód UT WoS článku

000500934300007

EID výsledku v databázi Scopus

2-s2.0-85075339756